Stephen Voyce is a Cardiology physician affiliated with Geisinger College of Health Sciences. OpenAlex indexes 49 publications with 828 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1800 Mulberry St
Scranton, PA 185102369
Telephone
570-703-4830Provider last certified this registry record 30 Jul 2020.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20242 payments
- Janssen Research & Development, LLCProgram year20239 payments
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.2%Beta blocker19.3%Metoprolol Succinate68%Metoprolol Tartrate21%Carvedilol12%Part D≥95 patientsStatin18.4%Rosuvastatin Calcium49%Atorvastatin Calcium48%Simvastatin3%Part D<11 patients+ 14 more classes in this area
Blood & clotting
15.6%Factor Xa inhibitor12.8%Eliquis78%Xarelto22%Part D≥52 patientsP2Y12 inhibitor1.9%Clopidogrel100%Part D≥16 patients+ 1 more class in this area
Metabolism & gastrointestinal
6.2%SGLT2 inhibitor6.2%Jardiance58%Farxiga42%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Moving triglycerides off the “back burner”: Developing a tailored approach to managing ASCVD risk in post-ACS patients
Journal of clinical lipidology
2025 - Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - Qualitative evaluation to understand barriers and facilitators to prescribing angiotensin receptor-neprilysin inhibitors (ARNi) and sodium-glucose cotransporter inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF)
Journal of the American Pharmacists Association
2024 - Evaluation of pharmacist-led transition of care program in patients with acute coronary syndrome
Journal of the American Pharmacists Association
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Conte, MD
Geisinger College of Health Sciences
Leighton Huey, MD
Geisinger College of Health Sciences
Evan Norfolk, MD
Geisinger College of Health Sciences
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”